Model Development for Pharmacokinetics / Pharmacodynamics of Antimicrobial Drugs in Blood Stream Infections Part 1: Feasibility Study
试验速览
- 阶段
- 不适用
- 入组人数
- 120
- 试验地点
- 4
- 主要终点
- Fraction of eligible patients
研究概览
简要总结
The current study is a pilot study to assess the feasibility of a superordinate project. The final objective of this superordinate project is to describe and model the pharmacokinetic behaviour of a small number of standard antimicrobials used in the treatment of frequent blood stream infections, and to link this via pharmacodynamic models to (inhibition of) bacterial or fungal growth as well as to clinical outcomes in patients.
详细描述
Patients with a high probability of a blood stream infection and an indication for antimicrobial treatment will be included. The study comprises the identification of patients as potential study participants, obtaining informed consent, documentation of available potential covariates from patient file, withdrawal of pre-study blood samples (PK, PD, microbiology) including documentation of exact time of sampling and processing of the samples, first drug administration including exact documentation (as part of patient care; not as a study intervention), withdrawal of subsequent blood samples (PK, PD, microbiology) during the next 3 days including documentation of exact time of sampling and processing of the samples, storage of processed samples for further analysis, and, if possible, documentation of patient outcome after 7 days. The following steps are carried out after completion of the clinical part of the study in the individual patient or, when possible, in all patients together or in a subset: Bioanalytics, DNA Counts, assessing primary and secondary study endpoints, pharmacometric analyses including PK parameter estimation, PD parameter estimation and assessment of covariate effects with regard to DNA count, CRP, IL-6 and procalcitonin.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •High probability of a blood stream infection; this is based on
- •the presence of SIRS [Bone et al. 1992] defined by more than one of the following clinical manifestations:
- •a body temperature greater than 38°C or less than 36°C
- •a heart rate greater than 90 beats per minute
- •tachypnea, manifested by a respiratory rate greater than 20 breaths per minute, or hyperventilation, as indicated by a PaCO2 of less than 32 mm Hg
- •an alteration in the white blood cell count, such as a count greater than 12,000/µl, a count less than 4,000/µl, or the presence of more than 10 percent immature neutrophils ("bands").
- •the assessment of the treating physician according to the patient's situation that the SIRS is caused by an infection (e.g., patients after treatment with cytotoxic drugs)
- •indication for antimicrobial treatment
- •Intended use of one of the following antimicrobial agents:
- •piperacillin/tazobactam; vancomycin; meropenem; ampicillin/sulbactam; flucloxacillin; ceftriaxone; caspofungin (according to the decision of the project coordinator, use of other antimicrobial agents may also be included if anticipated to be used frequently)
- •Age: 18 years or older (no upper limit)
- •Willing and capable to provide written consent prior to enrolment after ample information has been provided
排除标准
- •expected chances to successfully carry out venipunctures to obtain the blood samples required for the study are inadequately low according to the assessment of the physician
- •Anemia CTCAE grade >2 (i.e., Hb <8.0 g/dL / 4.9 mmol/L)
- •the clinical status of the patients suggests that the anticipated treatment of the patient or other conditions would make participation on the study inappropriate (e.g., terminally ill patients); the respective assessment is done by the treating physician
结局指标
主要结局
Fraction of eligible patients
时间窗: Screening
Fraction of identified and potentially eligible patients willing and able to provide informed consent
Positive blood microbial DNA count
时间窗: Samples for DNA counts are taken for a duration of up to 3 days.
Fraction of study participants having any positive blood microbial DNA count for microbes which does not reflect sample contamination
Fraction of patients with at least three samples with microbial DNA
时间窗: Samples for DNA counts are taken for a duration of up to 3 days.
Fraction of study participants with at least three samples with quantifiable microbial DNA along with a proper documentation
Plausible time courses of antimicrobial drug concentrations
时间窗: Samples for antimicrobial drug concentrations are taken for a duration of up to 3 days.
Fraction of study participants with plausible time courses of antimicrobial drug concentrations along with a proper documentation
次要结局
- Population pharmacokinetic parameters of drugs studied(Samples for antimicrobial drug concentrations are taken for a duration of up to 3 days.)
- Population pharmacodynamic parameters of drugs studied(Samples for antimicrobial drug concentrations are taken for a duration of up to 3 days.)
研究者
Prof. Dr. Uwe Fuhr
Director, Department I of Pharmacology
University of Cologne